|
| Press Releases |
|
 |
|
| Monday, June 27, 2022 |
|
|
醫思健康榮獲《機構投資者》2022亞洲區最佳管理團隊多個獎項 |
| 香港最大非醫院醫療服務機構* ── 醫思健康（「公司」，連同附屬公司，總稱「集團」；香港聯交所股份編號：2138）欣然公佈集團於國際金融權威雜誌《機構投資者》發布的2022年度「亞洲區最佳管理團隊」榜單中榮獲醫療健康及製藥類別多個獎項。 more info >> |
|
|
EC Healthcare Received "Institutional Investor" 2022 Multiple Awards in All-Asia Executive Team Rankings |
| EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong* more info >> |
|
| Thursday, June 23, 2022 |
|
|
医思健康公布2021/22年度全年业绩 |
| 香港最大非医院医疗服务机构* ── 医思健康（「公司」，连同附属公司，总称「集团」；香港联交所股份编号：2138）公布截至2022年3月31日止财政年度（「年内」）之经审核全年业绩。 more info >> |
|
|
醫思健康公佈2021/22年度全年業績 |
| 香港最大非醫院醫療服務機構* ── 醫思健康（「公司」，連同附屬公司，總稱「集團」；香港聯交所股份編號：2138）公佈截至2022年3月31日止財政年度（「年內」）之經審核全年業績。 more info >> |
|
|
EC Healthcare Announces FY2021/22 Annual Results |
EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, announces today its audited annual results for the fiscal year ended 31 March 2022 (the "Year").
more info >> |
|
| Tuesday, June 21, 2022 |
|
|
醫思健康訂立可持續發展表現掛鈎雙重貸款 開創香港醫療健康市場先河 |
| 香港最大非醫院醫療服務機構*──醫思健康（「公司」，連同附屬公司，總稱「集團」；香港聯交所股份編號：2138）欣然宣佈，集團首次訂立可持續發展表現掛鈎貸款（「可持續發展貸款」），總值為7億港元。 more info >> |
|
|
EC Healthcare Signs Inaugural Dual-Tranche Sustainability-Linked Facility, The First-of-its-Kind in Hong Kong Healthcare Industry |
| EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong* more info >> |
|
| Monday, June 6, 2022 |
|
|
医思健康携手凯龙瑞及亚洲联合基建成立合资公司 |
| 香港最大非医院医疗服务机构*──医思健康（「公司」，连同附属公司，统称「集团」；香港联交所股份编号：2138）欣然宣布，集团与房地产投资管理公司凯龙瑞集团（「凯龙瑞」）及亚洲联合基建控股有限公司（「亚洲联合基建」；香港联交所股份编号：0711）成立合资公司（「合资公司」） more info >> |
|
|
醫思健康攜手凱龍瑞及亞洲聯合基建成立合資公司 |
| 香港最大非醫院醫療服務機構*──醫思健康（「公司」，連同附屬公司，統稱「集團」；香港聯交所股份編號：2138）欣然宣佈，集團與房地產投資管理公司凱龍瑞集團（「凱龍瑞」）及亞洲聯合基建控股有限公司（「亞洲聯合基建」；香港聯交所股份編號：0711）成立合資公司（「合資公司」） more info >> |
|
|
EC Healthcare Forms a Joint Venture with KaiLong and Asia Allied Infrastructure |
| EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group formed a joint venture company (the "JV Company") with a real estate investment management company more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
珠宝双展匯聚逾82,000环球买家
Mar 9, 2025 13:51 HKT/SGT
|
|
|
珠寶雙展匯聚逾82,000環球買家
Mar 9, 2025 13:41 HKT/SGT
|
|
|
Twin jewellery shows attract over 82,000 global buyers
Mar 9, 2025 13:19 HKT/SGT
|
|
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million
Mar 8, 2025 19:40 HKT/SGT
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 8, 2025 19:20 HKT/SGT
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 21:26: JST
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 7, 2025 20:31: JST
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 20:26 HKT/SGT
|
|
|
雲頂新耀股價創3年新高 AI+mRNA賦能管線重塑估值
Mar 7, 2025 19:24 HKT/SGT
|
|
|
云顶新耀股价创3年新高 AI+mRNA赋能管线重塑估值
Mar 7, 2025 19:16 HKT/SGT
|
|
|
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙
Mar 7, 2025 18:28 HKT/SGT
|
|
|
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙
Mar 7, 2025 18:10 HKT/SGT
|
|
|
東信營銷科技：中國AI營銷龍頭斬獲多模態雙備案 技術實力獲國家級認證
Mar 7, 2025 17:58 HKT/SGT
|
|
|
东信营销科技：中国AI营销龙头斩获多模态双备案 技术实力获国家级认证
Mar 7, 2025 17:20 HKT/SGT
|
|
|
Japan's Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Mar 7, 2025 16:24 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
